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ABSTRACT
Methotrexate in combination with a calcineurin inhibitor is a standard graft-versus-host disease (GVHD)
prophylactic regimen in allogeneic stem cell transplantation. However, methotrexate is associated with delayed
engraftment, mucositis, idiopathic pneumonia syndrome, and other transplant-related complications. Siroli-
mus, a novel immunosuppressant without methotrexate’s toxicities, has been used successfully in solid organ
transplantation. We hypothesized that replacing methotrexate with sirolimus would preserve effective pro-
phylaxis of GVHD while minimizing transplant-related toxicity after allogeneic peripheral blood stem cell
transplantation. We enrolled 30 patients in a phase II study to test the efficacy of tacrolimus in combination
with sirolimus in lieu of methotrexate in preventing GVHD after allogeneic peripheral blood stem cell
transplantation from HLA-matched related donors. Grade II GVHD occurred in 3 patients (10%), and no
patient developed grade III or IV GVHD. Neutrophil and platelet engraftment were prompt, occurring on days
14 and 13, respectively. All patients survived to hospital discharge (median, 18 days), and peritransplantation
toxicity was mild. Four patients developed thrombotic microangiopathy, and 3 patients developed hepatic
veno-occlusive disease. Chronic GVHD occurred in 11 patients. Relapse-free and overall survival at 100 days
were 93% and 97%, respectively, and were 71% and 67% at 1 year. Causes of death included relapse (n  6),
veno-occlusive disease (n  1), and late pulmonary toxicity (n  1). Sirolimus in combination with tacrolimus
is a promising alternative to methotrexate-based regimens for GVHD prophylaxis after matched related donor
peripheral blood stem cell transplantation. Mucositis was modest, engraftment was prompt, and transplant-
related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be
tested in randomized trials against the current standard of care.
© 2004 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
Transplant-related toxicity and graft-versus-host
isease (GVHD) are the 2 most critical barriers to
uccessful allogeneic stem cell transplantation. The
ombination of a calcineurin inhibitor and methotrex-
te has been the standard GVHD prophylactic regi-
en for the past 20 years [1]. Despite these 2 agents,
cute GVHD occurs after 35% to 40% of matched c
28elated donor transplantations, and transplant-related
orbidity accounts for up to 25% of deaths in the
osttransplantation period [2].
Sirolimus is a lipophilic macrocyclic lactone with
ntifungal and immunosuppressive properties. Struc-
urally similar to tacrolimus, sirolimus complexes with
KBP12, binds mTOR, and blocks its function. The
eported downstream effects of mTOR inhibition in-
lude blockade of CD28 co-stimulation signals [3],
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Belective transcription and translation blockade, and a
ecrease in the kinase activity of vital cyclins, ulti-
ately leading to G1 cell-cycle arrest [4]. In contrast,
he tacrolimus/FKBP complex and the cyclosporin A/
yclophilin complex are immunosuppressive through
he inhibition of calcineurin [5,6]. Although there is
heoretical competition for FKBP binding sites be-
ween sirolimus and calcineurin inhibitors, these
gents seem to work synergistically [5,6]. Sirolimus
ay also impair dendritic cell maturation [7] and
ntigen uptake [8,9] and may trigger dendritic cell
poptosis [10,11]. Sirolimus has been used alone and
n combination with calcineurin inhibitors for the pre-
ention of allograft rejection after solid organ trans-
lantation [12,13] and as therapy for acute [14] and
hronic [15,16] GVHD. The predominant toxicities
f sirolimus are mild reversible cytopenia and hyper-
ipidemia with prolonged exposure. It is not associated
ith the neurotoxicity and nephrotoxicity of calci-
eurin inhibitors.
Methotrexate, used in conjunction with cyclospor-
ne, provides additional control of GVHD [1]; how-
ver, it is associated with complications after trans-
lantation. Methotrexate delays the time to neutrophil
ngraftment [1,17,18], worsens oral mucositis, and is
ssociated with pulmonary toxicity after transplanta-
ion [19]. We therefore sought to replace methotrex-
te with an immunosuppressive agent without these
imitations that could work synergistically with cal-
ineurin inhibitors.
In a previous trial, we showed that the combina-
ion of sirolimus, tacrolimus, and low-dose methotrex-
te, when used after HLA-matched unrelated bone
arrow transplantation, was associated with a rate of
rade II to IV GVHD of 26% [20]. The GVHD rate
fter matched related donor transplantation is lower
han that after unrelated donor transplantation; there-
ore, we believed that it would be safe to elimi-
ate methotrexate from the GVHD prophylaxis
egimen after matched related donor transplanta-
ion. We hypothesized that the use of sirolimus and
acrolimus would result in adequate control of GVHD
nd would reduce transplant-related morbidity and
ortality.
ETHODS
tudy Design
This was a 1-stage, phase II trial of sirolimus and
acrolimus as GVHD prophylaxis for patients under-
oing matched related donor allogeneic stem cell
ransplantation for hematologic malignancies. The
rimary end points of the trial were the incidence and
everity of acute GVHD when sirolimus and tacroli-
us are used in combination without additional meth-
trexate. Secondary end points included the incidence o
B&MTf serious complications after transplantation, the in-
idence and severity of mucositis after transplantation,
he time to ﬁrst hospital discharge, and survival at 100
ays and 1 year after transplantation.
Eligible patients had HLA-matched related do-
ors typed at high resolution for HLA class II and at
ntermediate resolution for HLA class I. Eligibility
equirements included age 18 years, Eastern Coop-
rative Oncology Group performance status 2, and
dequate measures of renal, hepatic, cardiac, and pul-
onary function. The study was approved by the
fﬁce for the Protection of Research Subjects at the
ana-Farber Cancer Institute, and all participating
ubjects signed informed consent.
tudy Therapy
Conditioning before transplantation consisted of
yclophosphamide (1800 mg/m2) on 2 consecutive
ays followed by total body irradiation (14.0 Gy; 7
ractions). Lung shielding was used. Tacrolimus was
dministered at 0.02 mg/kg/d intravenously by con-
inuous infusion beginning on day 3 (target serum
oncentration, 5-10 ng/mL). Tacrolimus was con-
erted to an equivalent oral dose before discharge.
irolimus was administered as a 12 mg oral loading
ose on day 3, followed by a 4 mg/d single morning
ral dose (target serum concentration, 3-12 ng/mL by
igh-performance liquid chromatography). Levels
ere monitored 3 times weekly while patients were
ospitalized and then as clinically indicated after dis-
harge. When clinically feasible, immunosuppressive
herapy was tapered at day 100 after transplantation
nd was eliminated by week 26.
Peripheral blood stem cells were mobilized from
elated donors by using ﬁlgrastim (Amgen, Thousand
aks, CA) at 10 g/kg daily for 5 days. Stem cells
ere harvested by large-volume leukapheresis in 1 to
sessions to obtain a target stem cell dose of 5  106
D34 cells per kilogram. The ﬁrst day of stem cell
nfusion corresponded to day 0. No methotrexate was
iven after transplantation.
All patients were received posttransplantation sup-
ortive care as previously described [20]. Posttrans-
lantation ﬁlgrastim was administered at 5 g/kg/d
rom day 12 until neutrophil engraftment occurred.
cute GVHD was graded according to the consensus
rading scale [21]. The incidence and severity of post-
ransplantation mucositis was prospectively recorded
pproximately twice weekly by trained oral evaluators
sing a validated 6-point site-speciﬁc mucositis scale
ased on the presence of erythema and extent of ul-
eration [22]. Chimerism was determined by single
andem repeat polymorphism analysis comparing
osttransplantation samples with pretransplantation
onor and recipient samples and with a 50% mixture
f donor and recipient cells [23]. At monthly intervals
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3fter transplantation, peripheral blood mononuclear
ells were isolated by Ficoll-Hypaque sedimentation
nd incubated at 4°C for 30 minutes with a panel of
onoclonal antibodies speciﬁc for CD3, CD4, CD8,
D20, CD45RO, CD45RA, and CD56 antigens con-
ugated to ﬂuorescein, phycoerythrin, PC5, or PC7
Coulter Immunology, Hialeah, FL). Immunopheno-
ypic analysis of the stained cells was performed on a
yomics FC500 (Beckman Coulter, Hialeah, FL).
tatistical Analysis
Sample size calculations were based on the as-
umption that an observed rate of GVHD 35%
ould be considered promising. The probability of
oncluding the proposed regimen promising is 0.84 if
he true but unknown incidence rate is 30% and is
.10 if the true but unknown incidence rate is 50%,
ith an exact binomial distribution.
Day 0 was considered the ﬁrst day of stem cell
nfusion, regardless of the total number of infusions
dministered. Neutrophil and platelet engraftment
ere deﬁned as the ﬁrst of 3 consecutive days of an
bsolute neutrophil count of 500/L or an unsup-
orted platelet count of 20000/L, respectively. Re-
apse-free survival was deﬁned as the time from trans-
lantation to relapse or death from any cause. Overall
urvival was deﬁned as the time from transplantation
o death from any cause. Patients alive without a
elapse reported were censored at the date of last
ontact. Time to engraftment, time to hospital dis-
harge, cumulative incidence of GVHD, relapse-free
urvival, and overall survival were calculated according
o the method of Kaplan and Meier [24]. Locally
eighted scatterplot smoothing, a smoothing curve
stimation technique, was used to explore the pattern
f longitudinal data on sirolimus levels [25].
ESULTS
atient Characteristics
Thirty patients were enrolled between July 1,
002, and May 15, 2003. A total of 86% of patients
ho underwent matched related donor transplanta-
ion during the enrollment period participated in the
rial. The 5 patients who were excluded during this
eriod were excluded because of prior stem cell trans-
lantation (n  2), preexisting hepatic insufﬁciency
n  1), the need for stem cell cryopreservation (n 
), and physician preference (n  1).
Twenty-nine patients received HLA-matched pe-
ipheral blood stem cells from siblings. One patient
eceived stem cells from a genotypically identical par-
nt. Patient characteristics are shown in Table 1. Ad-
quate serum concentrations of sirolimus, when given
rally, were attainable in all patients (Figure 1). Tar- m
30eted sirolimus levels were noted in 73.3% of mea-
ured values between days 0 and 100. Of the remain-
ng measurements, 14.4% were subtherapeutic (3
g/mL), and 12.3% were supratherapeutic (12 ng/
able 1. Baseline Characteristics
Variable Data
ample size 30
ge, y, median (range) 42 (19-54)
ex
Male 16 (53%)
Female 14 (47%)
tem cell source
PBSC 30 (100%)
onor
6/6 HLA-matched sibling 29 (97%)
6/6 HLA-matched parent 1 (3%)
iagnosis
AML 8 (27%)
CR1 3
CR > 1 2
Refractory/active disease 3
MDS 7 (23%)
Untreated RA/RARS 4
RAEB/RAEB-t 3
CML 7 (23%)
Chronic phase 6
Advanced 1
NHL 6 (20%)
Follicular 1
Diffuse large B cell 1
Burkitt lymphoma 1
CLL/SLL 1
Mantle cell lymphoma 1
Peripheral T-cell lymphoma 1
ALL 1 (3%)
Second remission 1
ATLL 1 (3%)
onor age, y, median (range) 42 (16-59)
ex matching (donor/recipient)
M/M 7 (23%)
M/F 6 (20%)
F/M 9 (30%)
F/F 8 (27%)
MV serostatus
(donor/recipient)
/ 9 (30%)
/ 6 (20%)
/ 2 (7%)
/ 10 (33%)
Unknown 3 (10%)
BSC indicates peripheral blood stem cells; AML, acute myeloge-
nous leukemia; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; NHL, non-Hodgkin lymphoma, ALL,
acute lymphoblastic lymphoma; ATLL, acute T-cell leukemia/
lymphoma; CR, complete remission; RA/RARS, refractory ane-
mia/refractory anemia with ringed sideroblasts; RAEB/RAEB-t,
refractory anemia with excess blasts/refractory anemia with ex-
cess blasts in transformation; M, male; F, female; CLL, chronic
lymphatic leukemia; SLL, small lymphocytic lymphoma.L).
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Btem Cell Products and Engraftment
The median number of CD34 stem cells infused
as 7.83 106/kg (range, 2.81-20.60 106/kg). Nine
atients received more than 1  107 cells per kilo-
ram, and 1 patient received fewer than 3  106
D34 cells per kilogram. All patients achieved stable
ematopoietic engraftment. The median time to neu-
rophil engraftment was 14 days (range, 1-17 days).
he median times to attain a platelet count of 20000
nd 100000/L were 13 days (range, 10-47 days) and
8 days (range, 11-189 days), respectively. Two pa-
ients relapsed before achieving a platelet count of
00000/L. All 30 patients survived to their ﬁrst hos-
ital discharge, which occurred at a median of 18 days
range, 15-54 days) from transplantation (Table 2;
igure 2). Complete donor hematopoietic chimerism
as noted in all samples tested within 100 days of
ransplantation. Reconstitution of B, T, and NK cells
Figure 1. Sirolimus levels du
able 2. Engraftment and GVHD End Points
Variable Data
edian days to ANC >500/L (range) 14 (11-17)
edian days to Plt >20 000/L (range) 13 (10-47)
edian days to Plt >100 000/L (range)* 19 (11-189)
edian days to first hospital discharge 18 (15-54)
cute GVHD
Grade 0-I 27 (90%)
Grade II 3 (10%)
Grade III-IV 0 (0%)
hronic GVHD† 11 (39%)
NC indicates absolute neutrophil count; Plt, platelets.
Two patients relapsed before achieving a platelet count of 100
000/L.
Two patients died before day 100 and were ineligible for chronic(GVHD analysis.
B&MTas notable for a decrease in the total number of
D8 T cells early after transplantation (Figure 3).
raft-versus-Host Disease
Three patients developed grade II acute GVHD at
1, 20, and 21 days from transplantation. The actuar-
al incidence of grade II acute GVHD was 10% at 100
ays (Figure 4). No patient developed grade III or IV
VHD. All 3 patients with grade II GVHD had
utaneous GVHD (maximum skin stage III), and 1
atient also had gastrointestinal involvement (maxi-
um gastrointestinal stage I). No patient developed
epatic GVHD. In total, 5 patients received systemic
herapy for grade I or II GVHD with corticosteroids,
ith or without daclizumab (1 mg/kg), as part of a
linded randomized trial examining initial therapy for
cute GVHD. One additional patient received low-
ose corticosteroids for therapy of intractable nausea
fter upper gastrointestinal endoscopy failed to docu-
ent histologic changes consistent with GVHD.
Chronic GVHD was reported in 11 of 28 evalu-
igure 2. Neutrophil and platelet engraftment and time to ﬁrst
ospital discharge. Neutrophil (- - -), discharge (– –), platelet
0 days after transplantation.——).
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3ble patients. Five patients had chronic GVHD lim-
ted to mucocutaneous organs, 4 had hepatic involve-
ent, and 2 had other organ involvement. The
edian time to development of chronic GVHD was
18 days. Chronic GVHD occurred in 6 patients
uring a taper of immunosuppression and in 5 patients
ho were receiving no immunosuppressive therapy.
wo of the 3 patients with grade II acute GVHD
eveloped chronic GVHD. There have been no
eaths attributable to acute or chronic GVHD.
oxicity
Regimen-related toxicity was moderate and is
hown in Table 3. No patient developed idiopathic
neumonia syndrome or diffuse alveolar hemorrhage.
hree patients developed severe veno-occlusive dis-
ase of the liver (VOD). Two of these patients had
igure 3. Immunologic reconstitution after transplantation. A,
D20 B cell, CD3 T cell and CD56 NK cell reconstitution. B, T
ell subset (CD4, CD8) reconstitution.bFigure 4. Cumulative incidence of grade II to IV GVHD.
32reviously been exposed to gemtuzumab ozogamycin,
known risk factor for VOD [26]. All 3 patients were
reated with the experimental agent deﬁbrotide [27].
OD was the cause of death in 1 patient, and the
ther 2 patients recovered normal hepatic function.
The syndrome of thrombotic microangiopathy
TMA), which includes renal dysfunction, microan-
iopathic hemolysis, and thrombocytopenia, occurred
n 4 patients (13%). As a result of TMA, 1 patient
equired temporary hemodialysis. All patients with
MA regained normal renal function. Before TMA
iagnosis, supratherapeutic serum tacrolimus and
irolimus levels were noted in 2 and 3 patients, respec-
ively. TMA was managed conservatively by discon-
inuing tacrolimus and withholding sirolimus until
enal function improved and serum levels fell into the
arget range. Temporary hemodialysis was required in
patient. All 4 patients regained normal renal func-
ion. Mycophenolate mofetil was substituted for ta-
rolimus in all patients with TMA. No patient
xperienced a recurrence when sirolimus was reintro-
uced.
Reactivation of cytomegalovirus (CMV) was noted
n only 1 patient despite 18 CMV-seropositive donor/
ecipient pairs at the time of transplantation. One
atient developed BK cystitis and viremia and was
reated with supportive care. No other patient devel-
ped an opportunistic infection or invasive fungal dis-
ase.
Oral mucositis was modest. Ten patients (33%)
eveloped nonulcerating mucositis (grade 0-1), and
nly 3 patients (10%) developed severe (grade 4) mu-
ositis. No patient developed grade 5 mucositis. As a
esult, the median number of days on total parenteral
utrition was 6 (range, 0-26 days), and 47% of patients
equired no parenteral nutrition during transplanta-
ion. Hypercholesterolemia and hypertriglyceridemia
ere noted in 3 patients each. Two patients experienced
able 3. Transplant-Related Toxicity
Variable Data
diopathic pneumonia syndrome 0 (0%)
eno-occlusive disease of the liver 3 (10%)
hrombotic microangiopathy 4 (13%)
MV reactivation 1 (3%)
K cystitis/viremia 1 (3%)
nvasive fungal infection 0 (0%)
ypercholesterolemia
CTC grade 2 3 (10%)
CTC grade 3 0 (0%)
CTC grade 4 0 (0%)
ypertriglyceridemia
CTC grade 2 1 (3%)
CTC grade 3 1 (3%)
CTC grade 4 1 (3%)
TC indicates common toxicity criteria.oth hypercholesterolemia and hypertriglyceridemia,
1
a
m
T
m
S
2
a
3
a
r
d
i
a
r
r
D
t
c
r
h
a
v
p
d
i
d
s
i
t
t
e
a
1
r
t
m
[
p
a
t
s
p
h
t
V
p
c
o
t
n
t
b
p
w
i
t
m
s
m
o
t
r
t
a
4
c
n
o
G
r
4
[
m
a
a
c
W
m
I
c
a
e
a
u
g
t
G
m
t
Tacrolimus and Sirolimus for GVHD
Bpatient experienced isolated hypercholesterolemia,
nd 1 patient experienced isolated hypertriglyceride-
ia as a result of prolonged exposure to sirolimus.
hese 4 patients were treated with 3-hydroxy-3-
ethylglutaryl/coenzyme A inhibitors.
urvival and Outcome
The median follow-up of transplant patients was
62 days, with a minimum follow-up of 6 months
mong surviving patients. Nonrelapse mortality was
% at 100 days and was 6% at 1 year (1 case of VOD
nd late pulmonary toxicity). Six patients with high-
isk disease at the time of transplantation relapsed and
ied of relapsed disease. All other patients remain alive
n complete clinical remission. Relapse-free and over-
ll survival at 100 days were 93% and 97%. At 1 year,
elapse-free and overall survival were 71% and 67%,
espectively (Figure 5).
ISCUSSION
Prevention of acute GVHD and minimization of
ransplant-related morbidity and mortality remain
ritical barriers to improved outcomes after matched
elated peripheral blood stem cell transplantation. We
ypothesized that methotrexate, an antiproliferative
gent commonly used for GVHD prophylaxis, ad-
ersely affects transplantation outcomes and that re-
lacement of methotrexate with sirolimus would re-
uce GVHD and minimize transplant-related toxicity.
The expected reduction in transplant-related tox-
city was evident. This reduction, hypothesized to be
ue to the omission of methotrexate, could have re-
ulted from several factors. The ﬁrst is the reduction
n the time to hematopoietic engraftment. The neu-
ropenic period, during which the incidence of infec-
ious, hemorrhagic, and other complications is great-
st, was reduced by several days. The median time to
ttain a neutrophil count of 500/L in this study was
4 days, which compares favorably to that in recent
andomized studies, in which the median time to neu-
rophil engraftment varied from 16 to 19 days when
Figure 5. Relapse-free and overall survival.ethotrexate and a calcineurin inhibitor were used b
B&MT28,29]. This is consistent with prior studies of trans-
lantation that compared methotrexate-containing
nd non–methotrexate-containing regimens [1,30].
The second mechanism possibly responsible for
he reduction in transplant-related toxicity is the ab-
ence of methotrexate-induced tissue injury. Idio-
athic pneumonia syndrome and diffuse alveolar
emorrhage, which have been associated with metho-
rexate use [19] were not noted in any treated patients.
OD of the liver occurred in only 1 patient not
reviously exposed to gemtuzumab ozogamycin. In
omparison, the incidence of these 2 important causes
f morbidity and mortality after stem cell transplan-
ation varies from 3% to 15% for idiopathic pneumo-
ia syndrome [31] and from 10% to 60% for VOD of
he liver [32]. Mucositis is a cause of signiﬁcant mor-
idity and reduction in quality of life after hemato-
oietic stem cell transplantation, and methotrexate,
hen given in conventional dosing regimens, is an
mportant contributor to this problem [33,34]. At-
empts to reduce the incidence and severity of oral
ucositis after transplantation have been largely un-
uccessful [33,35]. It is likely that the omission of
ethotrexate in this study led to the reduction in
bserved mucositis as well.
Previous attempts to eliminate or replace metho-
rexate in GVHD regimens have been unsuccessful. In
andomized studies in which methotrexate was omit-
ed or replaced with corticosteroids, acute [1,30,36,37]
nd chronic [38,39] GVHD rates were higher. The
-dose methotrexate regimen (45 mg/m2 total) is most
ommonly used after transplantation; however, alter-
ative and abbreviated regimens exist [40-45], and the
ptimal regimen is unknown. Grade II to IV acute
VHD rates have not been shown to be increased in
etrospective studies in which less than the standard
-dose methotrexate regimen was administered
18,46,47]. Furthermore, a single study of tacrolimus
onotherapy noted no difference in the incidence of
cute GVHD after bone marrow transplantation [48],
lthough monotherapy with tacrolimus was insufﬁ-
ient when peripheral blood stem cells were used [49].
e demonstrated that substitution of sirolimus for
ethotrexate was more effective in preventing grade
I to IV acute GVHD in comparison with historical
ontrols [28,29,45], with an actuarial rate of only 10%
t 100 days. This low incidence of GVHD was noted
ven as peripheral blood stem cells, whose use may be
ssociated with increased rates of acute GVHD, were
sed [50].
Methotrexate functions primarily by killing anti-
en-activated T cells; however, methotrexate causes
issue damage and can activate the initial phase of the
VHD response [51,52]. Sirolimus has multiple im-
unosuppressive effects, including impairment of an-
igen uptake by dendritic cells [8,9], and may therefore
lock the initiating and propagating events of GVHD.
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3n addition, proapoptotic signaling in dendritic cells
nduced by sirolimus [11] may minimize the potential
f dendritic cells to be potent stimulators of alloim-
unity. Sirolimus speciﬁcally inhibits CD8 T-cell
roliferation [53]; this effect was noted in our trial,
ith an inverted CD4/CD8 reconstitution ratio when
ompared with other studies of immune reconstitu-
ion [54]. Because CD8 T cells are important medi-
tors of GVHD [54], this may have contributed to
mproved GVHD control. Other contributing factors
o the excellent GVHD control include the prolonged
ourse of dual immunosuppressive therapy and the
act that the combination of sirolimus and tacrolimus
ay be more synergistic than combinations of siroli-
us and other calcineurin inhibitors [55].
The absence of GVHD in this trial was not cor-
elated with profound immunosuppression and poor
ngraftment, because all patients developed complete
onor chimerism by day 100. Similarly, the absence of
graft-versus-malignancy effect has not been noted,
ecause only patients with high-risk disease (relapsed
r refractory acute myelogenous leukemia, relapsed
cute lymphoblastic lymphoma, and Burkitt non-
odgkin lymphoma) have relapsed. Longer follow-up
ill be necessary to deﬁnitively comment on relapse
ates. Finally, the incidence of opportunistic infections
as low, with no invasive fungal infections, only 1 case
f CMV reactivation, and only 1 case of BK virus–
elated disease. Although other members of the siroli-
us family (such as RAD001 [everolimus]) may have
ntiviral properties, it is unclear whether this mecha-
ism of action played a role in the low incidence of
iral reactivation in this trial. More likely is the pos-
ibility that in the absence of acute GVHD, CMV
eactivation was suppressed.
Sirolimus and tacrolimus led to an apparent in-
rease in the rate of TMA in this study. The associa-
ion of TMA with cyclosporine or tacrolimus after
tem cell transplantation and solid organ transplanta-
ion is well known [56]. Recently, the combination of
irolimus and calcineurin inhibitors has been associ-
ted with this syndrome [57]. Sirolimus may promote
MA via direct endothelial damage or may potentiate
he effects of calcineurin inhibitors [58,59]; however,
here is only 1 case report of de novo TMA related to
irolimus monotherapy [60]. The mechanism respon-
ible for sirolimus-induced microangiopathy may be
olecular mimicry between sirolimus and tacrolimus,
ut conversion from tacrolimus to sirolimus immuno-
uppression as therapy for TMA without apparent
ntoward effects has been reported [61-63]. We sug-
est strict monitoring of tacrolimus and sirolimus lev-
ls when these drugs are used in combination to pre-
ent TMA.
In summary, we have shown that the substitution
f methotrexate with sirolimus is safe and effective for
he prevention of acute GVHD. This regimen is as-
34ociated with prompt engraftment, minimal trans-
lant-related morbidity and mortality, and minimal
ucositis. Sirolimus-containing, methotrexate-free
mmunosuppressive regimens offer the possibility of a
ajor advancement in GVHD prophylaxis and should
e tested against standard methotrexate regimens. If a
andomized trial against a standard methotrexate reg-
men conﬁrms our promising ﬁndings, then the siroli-
us/tacrolimus combination would be the ﬁrst major
odiﬁcation of GVHD prophylaxis in 20 years.
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